Navigation Links
Applied Computational Technologies Appoints a New CEO

Kathy Blum Will Help Drive the Commercialization of Company's Cancer

Therapy Product

PITTSBURGH, June 16 /PRNewswire/ -- Applied Computational Technologies (AppCompTech) has announced the appointment of Kathy Blum as the company's new Chief Executive Officer. With extensive experience in leading medical device, service and IT related businesses as well as global experience with start-ups and Fortune 500 organizations, Ms. Blum brings 27 years of industry knowledge and leadership with her as the new CEO of Applied Computational Technologies.

As CEO, Ms. Blum will be driving AppCompTech's mission to provide advanced radiation oncology treatment planning with ProACTive(TM) -- the company's groundbreaking software technology that is a dose calculation module which provides increased accuracy and greater speed in planning targeted radiation treatment.

"Ms. Blum will play a critical role in raising our final round of investment funding and positioning Applied Computational Technologies in the radiation therapy systems market," said Jay McClatchey, AppCompTech Co-founder. "Our software blends incredible speed with accuracy, enabling adaptive planning for a significant competitive advantage over existing treatment technology. We are all looking forward to working together to complete testing and bring our product ProACTive to market."

"In 2008 an estimated 1.4 million Americans will be diagnosed with cancer and approximately 65% of those cancer victims will receive some form of radiation therapy," said Ms. Blum. "I am honored to be part of an organization that is developing a product that can make radiation therapy more efficient and effective and help save more lives."

In addition, AppCompTech has formed an important strategic partnership with D3 Radiation Planning, a UPMC affiliated radiation oncology service company that offers advanced radiation treatment planning to hospitals and freestanding institutions. D3 will play a critical role in the testing and clinical evaluation of ProACTive. Hospitals and freestanding institutions currently utilize D3 to provide their patients with advanced radiation therapy planning for Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT). D3 has performed tens of thousands of treatment plans for over 75 customers worldwide.

About Applied Computational Technologies

Applied Computational Technologies is a software development company focused on a life sciences application in Radiation Treatment Planning for Cancer Therapy. Applied Computational Technologies' patented technology/software, called ProACTive(TM), shatters today's industry-wide speed barrier to high accuracy dose calculation for radiation therapy. The company blends incredible speed with accuracy, enabling adaptive planning for a significant competitive advantage over existing treatment technology.

SOURCE Applied Computational Technologies
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism
2. Hershey Center for Applied Research Supports Acceleration of Scientific Research and Development
3. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
4. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
5. Study Examines Media Preferences of Life Scientists in Applied Markets
6. Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing
7. Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
8. PAL Health Technologies Debuts Xtremityscan System at Western Podiatric Medical Congress
9. Senesco Technologies to Present at BIO 2008 Business Forum
10. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
11. Spine Surgeons at Pine Creek Medical Center Take the Lead in Utilizing Stem Cell Technologies in Surgical Procedures
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):